Elsevier

Neuropharmacology

Volume 33, Issue 12, December 1994, Pages 1589-1595
Neuropharmacology

Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (‘Ecstasy’) to rats

https://doi.org/10.1016/0028-3908(94)90134-1Get rights and content

Abstract

An investigation has been made into the effect of 3,4-methylenedioxymethamphetamine (MDMA or ‘Ecstasy’) administration on the concentration of 5-hydroxytryptamine (5-HT), uptake of [3H]5-HT and [3H]paroxetine binding in rat cerebral cortex tissue. Four days after 2 injections of MDMA (20 mg/kg i.p., 6 hr apart) the concentrations of 5-HT and its metabolite 5-HIAA were reduced by 60%. The binding of [3H]paroxetine to the presynaptic 5-HT transporter was decreased and high affinity uptake of [3H]5-HT was reduced by a similar amount, indicating neurodegeneration of 5-HT terminals. Pretreatment with chlormethiazole (100 mg/kg i.p.), 10 min before each MDMA injection prevented the decrease in both [3H]parotextine binding and uptake of [3H]5-HT. The loss in 5-HT and 5-HIAA content was also attenuated. Pretreatment with dizocilpine (1 mg/kg i.p.) or haloperidol (2 mg/kg i.p.) also prevented the MDMA-induced loss of [3H]paroxetine binding and attenuated the loss of 5-HT and 5-HIAA content. All three compounds also decreased the degree of hyperthermia that follows MDMA administration, although previous studies suggest that the long term neurodegeneration is not associated with the acute hyperthermic response. These data support the findings of others that MDMA injection produces degeneration of 5-HT nerve terminals in the cortex, confirm that chlormethiazole, dizocilpine and haloperidol attenuate MDMA-induced neurotoxic loss of 5-HT and demonstrate for the first time that these compounds prevent the neurodegeneration of 5-HT nerve terminals that follows MDMA administration.

References (37)

  • C.J. Schmidt et al.

    Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine

    Eur. J. Pharmac.

    (1990)
  • C.J. Schmidt et al.

    L-Dopa potentiation of serotonergic deficits due to a single administration of 3,4-methylenedioxymethampetamine, p-chloroamphetamine or methamphetamine to rats

    Eur. J. Pharmac.

    (1991)
  • D.M. Stone et al.

    The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain

    Eur. J. Pharmac.

    (1986)
  • R.P. Allen et al.

    Persistent effects of ( + )-3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on human sleep

    Sleep

    (1993)
  • G. Battaglia et al.

    3,4,Methylenedioxymethamphetamine and 3,4,methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]-paroxetine-labelled serotonin uptake sites

    J. Pharmac. Exp. Ther.

    (1987)
  • M.I. Colado et al.

    A study of the mechanism of MDMA (‘Ecstasy’)-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds

    Br. J. Pharmac.

    (1994)
  • M.I. Colado et al.

    5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine

    Br. J. Pharmac.

    (1993)
  • D.L. Commins et al.

    Biochemical and histological evidence that methylenedioxymethyl-amphetamine (MDMA) is toxic to neurons in the rat brain

    J. Pharmac. Exp. Ther.

    (1987)
  • Cited by (77)

    • Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine

      2014, Neuropharmacology
      Citation Excerpt :

      There is a substantial body of evidence that glutamate antagonists are neuroprotective (Colado and Green, 1994), although the protection may primarily result from the drugs lowering body temperature (Colado et al., 1998). The GABAmimetic clomethiazole protects against MDMA-induced neurotoxicity (Colado and Green, 1994; Hewitt and Green, 1994) as does the nNOS inhibitor AR-R17477AR (Sanchez et al., 2003). The free radical trapping agent PBN protects against MDMA-induced damage (Colado and Green, 1995) and further experiments demonstrated that this was due to radical trapping in the brain (Colado et al., 1997).

    • Gender differences in hyperthermia and regional 5-HT and 5-HIAA depletion in the brain following MDMA administration in rats

      2011, Brain Research
      Citation Excerpt :

      Another reason for concern is the long-lasting, possibly neurotoxic consequences of MDMA for the serotonergic system. Several preclinical studies have demonstrated that MDMA evokes a persistent decrease in serotonin and 5-hydroxyindoleacetic acid (5-HIAA), a reduction in tryptophan hydroxylase (TPH) activity, a reduction of serotonin transporter (SERT) activity and expression and finally a long-term impairment of anterograde transport in serotonin axons (Battaglia et al., 1987; Buchert et al., 2004; Callahan et al., 2001; Colado et al., 1993; Hewitt and Green, 1994; Ricaurte et al., 2000; Schmidt and Taylor, 1987; Semple et al., 1999; Sharkey et al., 1991; Stone et al., 1986; Xie et al., 2006). Although clinical studies on this matter are less conclusive, there is increasing evidence that MDMA can be toxic for the human brain too. (de Win et al., 2004; Grob, 2002; McCann et al., 2000; Turner and Parrott, 2000).

    View all citing articles on Scopus
    View full text